Results 31 to 40 of about 982,298 (304)

Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression [PDF]

, 2010
Background A significant genetic component has been described for idiopathic pulmonary fibrosis (IPF). The R131H (rs1801274) polymorphism of the IgG receptor FcγRIIa determines receptor affinity for IgG subclasses and is associated with several chronic ...
Hart Simon P, Wallace, William A., McFarlane, Pauline, Bournazos, Stylianos, Bournazos Stylianos, Alexander, Karen M, Karen M Alexander, Jacob Grinfeld, William A Wallace, Simpson A John, Hirani, Nikhil, McFarlane Pauline, Pauline McFarlane, Grinfeld Jacob, Grinfeld, Jacob, Hirani Nikhil, Simpson, A John, John T Murchison, Nikhil Hirani, Wallace William A, Hart, Simon P, Simpson, A. John, Dransfield, Ian, Stylianos Bournazos, Murchison John T, Alexander Karen M, Murchison, John T, Wallace, William, Ian Dransfield, Dransfield Ian, A John Simpson, Simon P Hart   +31 more
core   +2 more sources

Alveolar cells under mechanical stressed niche: critical contributors to pulmonary fibrosis

Molecular Medicine, 2020
Pulmonary fibrosis arises from the repeated epithelial mild injuries and insufficient repair lead to over activation of fibroblasts and excessive deposition of extracellular matrix, which result in a mechanical stretched niche.
Juntang Yang, Xin Pan, Lan Wang, Guoying Yu   +3 more
doaj   +1 more source

Rare and common variants in KIF15 contribute to genetic risk of idiopathic pulmonary fibrosis [PDF]

, 2022
RATIONALE: Genetic studies of Idiopathic Pulmonary Fibrosis (IPF) have improved our understanding of this disease, but not all causal loci have been identified.
Newton, Chad A, Povysil, Gundula, Martinez, Fernando J, Garcia, Joseph A, Petrovski, Slavé, Li, Qi, Maher, Toby M, Garcia, Christine Kim, Kobeissy, Philippe H, Raghu, Ganesh, Amelotte, Mason, Goldstein, David B, Haefliger, Carolina, Wang, Binhan, Molyneaux, Philip L, Jaouadi, Hager, Noth, Imre, Todd, Jamie L, Palmer, Scott M, Platt, Adam, Zhang, David   +20 more
core   +1 more source

Informal caregivers experience of supplemental oxygen in pulmonary fibrosis

Health and Quality of Life Outcomes, 2017
Background Patients prescribed supplemental oxygen (O2) therapy face challenges as they adjust to being constantly “tethered” to an oxygen delivery device.
Bridget A. Graney, Frederick S. Wamboldt, Susan Baird, Tara Churney, Kaitlin Fier, Marjorie Korn, Mark McCormick, Thomas Vierzba, Jeffrey J. Swigris   +8 more
doaj   +1 more source

Idiopathic pulmonary fibrosis

Medicina Clínica (English Edition), 2022
Idiopathic pulmonary fibrosis is defined as a chronic progressive fibrosing interstitial pneumonia of unknown etiology. There are intrinsic and extrinsic risk factors that could favor the development of the disease in individuals with a genetic predisposition.
Francisco, León-Román, Claudia, Valenzuela, María, Molina-Molina   +2 more
openaire   +6 more sources

Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events [PDF]

, 2014
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival.
Per M. Hellström, Groves, Richard, Michael Kreuter, Toby M. Maher, Maher, Toby M, Dewint, P. (Pieter), Sarafidis, A. (Alexandre), Vancheri, C. (Carlo), Egan, Jim JJ, Bendstrup, Elisabeth, Maher, T.M. (Toby), Bendstrup, E. (Elisabeth), Sarafidis, Alexandre, Egan, Jim J J, Vancheri, Carlo, Jim J. J. Egan, Costabel, Ulrich, Ferguson, James, Vincent Cottin, Nordlind, K. (Klas), Cottin, V. (Vincent), Hellström, Per M, Maher, Toby M., Carlo Vancheri, Richard Groves, Groves, R. (Richard), Costabel, U., Klas Nordlind, Dewint, Pieter, Nordlind, Klas, Cottin, Vincent, Ulrich Costabel, Ferguson, J.J. (James), Hellström, A.-L., Alexandre Sarafidis, Pieter Dewint, Egan, Jim J. J., Elisabeth Bendstrup, Kreuter, M. (Michael), Maria Molina-Molina, Molina-Molina, M. (Maria), James Ferguson, Kreuter, Michael, Egan, J.J.J. (Jim J.), Molina-Molina, Maria, Hellström, Per M., Hellström, Per M.,   +46 more
core   +1 more source

Obstructive sleep apnea and nocturnal hypoxemia in adult patients with cystic fibrosis

BMC Pulmonary Medicine, 2022
Background Obstructive sleep apnea (OSA), nocturnal hypoxemia and excessive daytime sleepiness (EDS) are common comorbidities in people with cystic fibrosis (pwCF). Most of the data showing this originates from children and adolescents.
Matthias Welsner, Sarah Dietz-Terjung, Florian Stehling, Tim Schulte, Ute Niehammer, Fatma-Ezzahra Gahbiche, Christian Taube, Svenja Strassburg, Christoph Schoebel, Gerhard Weinreich, Sivagurunathan Sutharsan   +10 more
doaj   +1 more source

Pulmonary rehabilitation in idiopathic pulmonary fibrosis and COPD: a propensity matched real-world study [PDF]

, 2021
BACKGROUND: The adherence to and clinical efficacy of pulmonary rehabilitation in idiopathic pulmonary fibrosis (IPF), particularly in comparison to people with chronic obstructive pulmonary disease (COPD), remains uncertain.
Ingram, Karen A, Walsh, JA, Polgar, O, Maher, Toby M, Schofield, SJ, Walsh, Jessica A, George, Peter M, Man, William D-C, Patel, Suhani, Maher, TM, Man, WDC, Molyneaux, Philip L, Nolan, CM, Ingram, KA, Patel, S, Polgar, Oliver, Schofield, Susie J, Molyneaux, PL, Nolan, Claire M, Barker, Ruth E, George, PM, Barker, RE   +21 more
core   +1 more source

Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome. [PDF]

, 2012
The state of oligomerization of surfactant associated protein-A (SP-A) monomers differs between individuals. This likely affects SP-A's functional properties and could thereby influence clinical status in patients with lung diseases.
Karl Paul, Matthias Kappler, Michael Kabesch, Stephanie Heinrich, Paul, Karl, Rietschel, Ernst, Griese, Matthias, Kappler, Matthias, Kabesch, Michael, Ratjen, Felix, Heinrich, Stephanie, Ballmann, Manfred, Matthias Griese, Felix Ratjen, Ernst Rietschel, Manfred Ballmann   +15 more
core   +1 more source

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report

BMC Pulmonary Medicine, 2019
Background CFTR modulator therapy with ivacaftor is a treatment option for Cystic Fibrosis (CF) patients with at least one copy of a R117H-7T mutation in the CFTR gene.
Matthias Welsner, Svenja Straßburg, Christian Taube, Sivagurunathan Sutharsan   +3 more
doaj   +1 more source